103 related articles for article (PubMed ID: 33220463)
21. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
22. Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment.
Zhang X; Qin B; Wang M; Feng J; Zhang C; Zhu C; He S; Liu H; Wang Y; Averick SE; Vo NTN; Huang L; Liu W; Wang Z
Int J Nanomedicine; 2022; 17():953-967. PubMed ID: 35280336
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.
Zhao W; Zhang Y; Jiang X; Cui C
Drug Des Devel Ther; 2016; 10():3851-3865. PubMed ID: 27920500
[TBL] [Abstract][Full Text] [Related]
24. Phenylboronic acid-functionalized polyamidoamine-mediated Bcl-2 siRNA delivery for inhibiting the cell proliferation.
Wu D; Yang J; Xing Z; Han H; Wang T; Zhang A; Yang Y; Li Q
Colloids Surf B Biointerfaces; 2016 Oct; 146():318-25. PubMed ID: 27371891
[TBL] [Abstract][Full Text] [Related]
25. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
[TBL] [Abstract][Full Text] [Related]
26. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
27. Biocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors.
Gao P; Zhang X; Wang H; Zhang Q; Li H; Li Y; Duan Y
Oncotarget; 2016 Jan; 7(3):2855-66. PubMed ID: 26625203
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and characterization of Fe
Arami S; Rashidi MR; Mahdavi M; Fathi M; Entezami AA
Hum Exp Toxicol; 2017 Mar; 36(3):227-237. PubMed ID: 27162247
[TBL] [Abstract][Full Text] [Related]
29. A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo.
Ewe A; Przybylski S; Burkhardt J; Janke A; Appelhans D; Aigner A
J Control Release; 2016 May; 230():13-25. PubMed ID: 27061141
[TBL] [Abstract][Full Text] [Related]
30. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
31. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice.
Wang XL; Xu R; Wu X; Gillespie D; Jensen R; Lu ZR
Mol Pharm; 2009; 6(3):738-46. PubMed ID: 19296675
[TBL] [Abstract][Full Text] [Related]
32. Targeted and Efficient Delivery of siRNA Using Tunable Polymeric Hybrid Micelles for Tumor Therapy.
Hao F; Dong S; Yang C; Li Z; Cheng Z; Zhong L; Teng L; Meng Q; Lu J; Wu F; Xie J; Teng L; Lee RJ
Anticancer Res; 2019 Mar; 39(3):1169-1178. PubMed ID: 30842146
[TBL] [Abstract][Full Text] [Related]
33. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
34. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
35. The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA.
Xu C; Tian H; Wang P; Wang Y; Chen X
Biomater Sci; 2016 Oct; 4(11):1646-1654. PubMed ID: 27709139
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis induction activity and molecular docking studies of survivin siRNA carried by Fe
Arami S; Mahdavi M; Rashidi MR; Yekta R; Rahnamay M; Molavi L; Hejazi MS; Samadi N
J Pharm Biomed Anal; 2017 Aug; 142():145-154. PubMed ID: 28505590
[TBL] [Abstract][Full Text] [Related]
37. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
Choi KM; Jang M; Kim JH; Ahn HJ
Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094
[TBL] [Abstract][Full Text] [Related]
38. Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors.
Jugel W; Aigner A; Michen S; Hagstotz A; Ewe A; Appelhans D; Schackert G; Temme A; Tietze S
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34066833
[TBL] [Abstract][Full Text] [Related]
39. Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles.
Unsoy G; Gunduz U
Expert Rev Anticancer Ther; 2016 Jul; 16(7):789-97. PubMed ID: 27130312
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
